Market Cap | 36.62M | P/E | - | EPS this Y | -34.60% | Ern Qtrly Grth | - |
Income | -44.22M | Forward P/E | -0.70 | EPS next Y | 33.10% | 50D Avg Chg | -34.00% |
Sales | 12M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -30.00% |
Dividend | N/A | Price/Book | 3.36 | EPS next 5Y | - | 52W High Chg | -55.00% |
Recommedations | 2.00 | Quick Ratio | 1.63 | Shares Outstanding | 22.63M | 52W Low Chg | 31.00% |
Insider Own | 0.05% | ROA | -63.71% | Shares Float | 488.15M | Beta | 1.47 |
Inst Own | 15.48% | ROE | - | Shares Shorted/Prior | 250.19K/290.51K | Price | 2.24 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 153,030 | Target Price | 9.50 |
Oper. Margin | -364.46% | Earnings Date | May 3 | Volume | 56,753 | Change | -5.49% |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
HC Wainwright & Co. | Buy | Apr 23, 24 |
HC Wainwright & Co. | Buy | Apr 15, 24 |
HC Wainwright & Co. | Buy | Mar 18, 24 |
Piper Sandler | Overweight | Mar 13, 24 |
Piper Sandler | Overweight | Mar 11, 24 |
HC Wainwright & Co. | Buy | Nov 6, 23 |
Roth MKM | Buy | Aug 14, 23 |
HC Wainwright & Co. | Buy | Aug 14, 23 |
HC Wainwright & Co. | Buy | Jul 7, 23 |